MedPath

Metacognitive therapy vs. exposure and response prevention for obsessive-compulsive disorder: A randomized clinical trial.

Recruiting
Conditions
obsessional problems
obsessive disorder
OCD
10002861
Registration Number
NL-OMON42263
Lead Sponsor
PsyQ Rijnmond, onderdeel van parnassia bavo groep
Brief Summary

Trial is onging in other countries

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
90
Inclusion Criteria

Primary diagnosis of obsessive-compulsive disorder, age between 18-65

Exclusion Criteria

To enhance the clinical representativeness of the sample, exclusion criteria will be kept to a minimum. Patients are only excluded if they currently:
1) meet DSM-V criteria for severe major depressive disorder that requires immediate treatment, psychotic disorder, or bipolar disorder
2) have mental impairment or evidence of organic brain disorder
3) have substance abuse requiring specialist treatment
4) have a change in medication type or dose in the six weeks before assessment or during treatment.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Treatment outcome will be evaluated by means of the Dutch versions of both a<br /><br>standardized self-report scale (Padua Inventory; Burns et al., 1996) and a<br /><br>semi-structured interview (Yale-Brown Obsessive Compulsive Scale [Y-BOCS];<br /><br>Goodman et al., 1989) for measuring the core symptoms of OCD (primary<br /><br>outcomes). Additionally, we will do a SCID-I screening.<br /><br><br /><br>To study changes in both belief domains that have been proposed to be important<br /><br>in the etiology of OCD and metacognitive beliefs about the meaning,<br /><br>significance, and danger of intrusive thoughts, the Obsessive Beliefs<br /><br>Questionnaire-44 (OBQ-44; OCCWG, 2005) and the Thought Fusion Instrument (TFI;<br /><br>Wells et al., 2001) will be employed. </p><br>
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath